You are here

New breast cancer drug data a boost for Eli Lilly

Adding its medicine abemaciclib to standard therapy reduces risk of disease progression by 46%; its efficacy is seen as comparable to that of rival drugs from Pfizer, Novartis

New York

ELI Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 per cent.

Experts at the European Society for Medical

sentifi.com

Market voices on: